PRAK 03202
Alternative Names: Coronavirus vaccine - Akers Biosciences/Premas Biotech; PRAK-03202; PRAK3202Latest Information Update: 28 Aug 2024
At a glance
- Originator Premas Biotech
- Class Peptide vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in India (IM)
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (IM)
- 27 Aug 2020 Premas Biotech announces intention to submit IND application to the US FDA and Drugs Controller General of India for COVID-2019 infections